Risk Factors for Drusen Progression
NCT01830608 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-04-08
Summary
Age-related macular degeneration (AMD) is the leading cause of blindness in the Western World. The etiology and pathogenesis of this disease remain largely unknown. In Europe about two million people suffer from AMD. According to the Age-Related Eye Disease Study (AREDS) the disease can be classified into early, intermediate and late. Early age-related macular degeneration is characterized by the presence of small or medium-sized drusen and/or retinal pigmentary abnormalities. Intermediate age-related macular degeneration is characterized by large drusen or numerous medium-size drusen and/or geographic atrophy not extending to the center of the macula. Late age-related macular degeneration can be either atrophic with extension to the macula or neovascular. The late form of the disease is associated with a pronounced loss of visual acuity.
In the recent years several studies focused on risk factors for late AMD and a recent systematic review and meta-analysis reported risk factors for AMD based on 16 studies in almost 114000 subjects. Strong and consistent associations with late AMD for found for increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD. Consistent associations between late AMD and higher body mass index, history of cardiovascular disease, hypertension and higher plasma fibrinogen were also found, but the association was weak. Inconsistent associations were found for gender, ethnicity, diabetes, iris color, history of cerebrovascular disease, serum total and HDL cholesterol and triglyceride levels.
Evidence has also accumulated that other factors influence the risk for AMD. Several genetic risk factors have been identified in the last years including genes in the alternative complement pathway and the RMS2/HTRA1 region. In addition, post-hoc analysis of data from the AREDS study has indicated that reduced intake of the omega-3 free fatty acids eicosapentaenoic acid and docsahexaenoic acid are associated with the risk of late AMD thereby supporting previous population based studies. The AREDS study also revealed that reduced intake of the macular pigment lutein and zeaxanthin may be associated with late AMD, again supporting previous population-based studies. Finally, 2 small studies indicate that reduced choroidal blood flow is associated with an increased risk of developing late AMD.
Less data are available for the progression of early or intermediate AMD and the associated risk factors. This is at least partially related to the problems in quantifying progression of drusen size and volume. In the recent years, however, significant efforts have been achieved in optical coherence tomography (OCT)-based methods for quantifying drusen progression and drusen volume. Polarization-sensitive OCT is the most promising of these approaches and will be used to quantify drusen area and volume in the present study.
Conditions
- Age-related Macular Degeneration
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-31
- Primary Completion
- 2015-03-31
- Completion
- 2015-03-31
Countries
- Austria
Study Locations
More Related Trials
-
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272 ·Status: RECRUITING
-
The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration
NCT07060196 ·Status: NOT_YET_RECRUITING
-
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
NCT06717139 ·Status: ACTIVE_NOT_RECRUITING
-
Directional Spread in Geographic Atrophy
NCT02051998 ·Status: COMPLETED
-
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
NCT05698316 ·Status: COMPLETED
-
Imaging of the Angiofibrotic Switch in Neovascular AMD
NCT03838679 ·Status: UNKNOWN
-
Stratus Versus Cirrus OCT in AMD
NCT00568191 ·Status: UNKNOWN
-
Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02941263 ·Status: COMPLETED
-
Study on Visual Function Impairments in Dry Age-related Macular Degeneration
NCT01822873 ·Status: COMPLETED
-
Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration
NCT04241536 ·Status: COMPLETED ·Phase: NA
-
Sparing of the Fovea in Geographic Atrophy Progression
NCT02332343 ·Status: COMPLETED
-
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
NCT01174407 ·Status: UNKNOWN
-
Ocular, Vascular, and Genetic Findings in AMD Patients
NCT06015633 ·Status: ACTIVE_NOT_RECRUITING
-
Progression of Early Atrophic Lesions
NCT05959005 ·Status: RECRUITING
-
Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration
NCT01777984 ·Status: UNKNOWN
-
AMD Phenotype and Genotype Study
NCT01778491 ·Status: COMPLETED
-
Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients
NCT02863640 ·Status: TERMINATED
-
Prediction of Progression of Age-Related Macular Degeneration
NCT04640649 ·Status: UNKNOWN ·Phase: NA
-
Study of Dark Adaptation in Age-Related Macular Degeneration
NCT01352975 ·Status: ACTIVE_NOT_RECRUITING
-
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
NCT01272063 ·Status: COMPLETED
-
Virtual Reality Based Vision Test in Patients With AMD
NCT06241625 ·Status: UNKNOWN ·Phase: NA
-
10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes
NCT04650165 ·Status: COMPLETED
-
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
NCT02173496 ·Status: COMPLETED
-
Direct Discrimination of Quantum States by the Human Eye
NCT05913063 ·Status: RECRUITING ·Phase: NA
-
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
NCT06351670 ·Status: RECRUITING